First “Post-Nesp” Renal Anemia Med Could Land Japan Approval in September

Astellas Pharma’s roxadustat could gain Japanese approval as early as September as the first product in the class of drugs called hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, which are hailed as “post erythropoiesis-stimulating agent (ESA)” treatments for renal anemia. Roxadustat,...read more